




1/13

**FIG. 1**

2/13

**FIG. 2**

3/13

**FIG. 3**






FIG. 4


5/13

**FIG. 5**

6/13

**FIG. 6**

7/13

**FIG. 7**






FIG. 8


9/13

**FIG. 9**


10/13

**FIG. 10**

11/13

**FIG. 11**

12/13

**FIG. 12**




FIG. 13

combination	Training set (n=251)				Validation set (n=182)			
	TP53 mutation status		baseline CDKN1A gene expression		TP53 mutation status		baseline CDKN1A gene expression	
	partial eta-squared	Pr>F	partial eta-squared	Pr>F	partial eta-squared	Pr>F	partial eta-squared	Pr>F
I-G-32/ gemcitabine	0.056	2.3E-04	0.173	1.0E-11	0.052	8.6E-03	0.114	7.3E-05
IIA-7/gemcitabine	0.075	1.9E-05	0.14	1.3E-09	0.029	3.5E-02	0.137	2.6E-06
I-G-32/cisplatin	0.044	2.5E-03	0.073	7.0E-05	0.039	1.5E-02	0.145	1.2E-06
IIA-7/cisplatin	0.027	1.8E-02	0.043	2.4E-03	0.048	8.2E-03	0.083	4.7E-04

FIG. 14